Product Description
NIO-752 is a drug candidate from Novartis Pharmaceutical for use in patients with progressive supranuclear palsy (PSP). (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04539041)
Mechanisms of Action: Tau Antagonist
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Novartis
Company Location: Europe
Company Founding Year: 1996
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, China, Finland, France, Germany, Italy, Japan, Netherlands, South Korea, Spain, Sweden, United Kingdom, United States
Active Clinical Trial Count: 6
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Respiratory Distress Syndrome|Pick Disease of the Brain|Progressive Supranuclear Palsy|Supranuclear Palsy, Progressive
Phase 1: Alzheimer Disease|Arthrogryposis|Brain Diseases|Cognitive Dysfunction|Memory Disorders|Paralysis|Tauopathies
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05469360 |
CNIO752B12201 | P1 |
Active, not recruiting |
Tauopathies|Alzheimer Disease|Brain Diseases|Memory Disorders|Cognitive Dysfunction |
2026-07-30 |
50% |
2026-06-04 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date |
NCT06372821 |
NIO-SILK | P1 |
Recruiting |
Arthrogryposis|Alzheimer Disease |
2026-07-01 |
2025-07-31 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT04539041 |
CNIO752A02101 | P1 |
Completed |
Progressive Supranuclear Palsy|Paralysis|Supranuclear Palsy, Progressive |
2024-10-17 |
2024-11-21 |
Primary Endpoints|Treatments|Trial Status |
|
NCT07498426 |
CNIO752A12301 | P3 |
Recruiting |
Pick Disease of the Brain|Progressive Supranuclear Palsy|Acute Respiratory Distress Syndrome|Supranuclear Palsy, Progressive |
2029-07-20 |
49% |
2026-07-30 |
Primary Endpoints|Treatments |
jRCT2031260029 |
jRCT2031260029 | P3 |
Not yet recruiting |
Progressive Supranuclear Palsy|Acute Respiratory Distress Syndrome|Supranuclear Palsy, Progressive |
2031-10-31 |
|||
2025-523481-24-00 |
CNIO752A12301 | P3 |
Not yet recruiting |
Acute Respiratory Distress Syndrome|Progressive Supranuclear Palsy|Supranuclear Palsy, Progressive |
2031-03-20 |
Recent News Events
Date |
Type |
Title |
|---|